Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:CYCC's Cash-to-Debt is ranked higher than
93% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. NAS:CYCC: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:CYCC' s Cash-to-Debt Range Over the Past 10 Years
Min: 1  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.75
NAS:CYCC's Equity-to-Asset is ranked higher than
63% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. NAS:CYCC: 0.75 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:CYCC' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.51  Med: 0.76 Max: 0.88
Current: 0.75
-3.51
0.88
Interest Coverage No Debt
NAS:CYCC's Interest Coverage is ranked higher than
91% of the 463 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:CYCC: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:CYCC' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: -19.96
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -1503.75
NAS:CYCC's Operating Margin % is ranked lower than
81% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -92.73 vs. NAS:CYCC: -1503.75 )
Ranked among companies with meaningful Operating Margin % only.
NAS:CYCC' s Operating Margin % Range Over the Past 10 Years
Min: -25222.48  Med: -4811.63 Max: -831.79
Current: -1503.75
-25222.48
-831.79
Net Margin % -1248.83
NAS:CYCC's Net Margin % is ranked lower than
79% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -81.52 vs. NAS:CYCC: -1248.83 )
Ranked among companies with meaningful Net Margin % only.
NAS:CYCC' s Net Margin % Range Over the Past 10 Years
Min: -19110.14  Med: -4605.02 Max: -737.76
Current: -1248.83
-19110.14
-737.76
ROE % -72.46
NAS:CYCC's ROE % is ranked lower than
70% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -38.58 vs. NAS:CYCC: -72.46 )
Ranked among companies with meaningful ROE % only.
NAS:CYCC' s ROE % Range Over the Past 10 Years
Min: -156.88  Med: -98.34 Max: -42.99
Current: -72.46
-156.88
-42.99
ROA % -53.68
NAS:CYCC's ROA % is ranked lower than
66% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -33.01 vs. NAS:CYCC: -53.68 )
Ranked among companies with meaningful ROA % only.
NAS:CYCC' s ROA % Range Over the Past 10 Years
Min: -86.17  Med: -58.95 Max: -34.56
Current: -53.68
-86.17
-34.56
ROC (Joel Greenblatt) % -9441.48
NAS:CYCC's ROC (Joel Greenblatt) % is ranked lower than
85% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -496.85 vs. NAS:CYCC: -9441.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:CYCC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -10207.43  Med: -3822.33 Max: -1007.24
Current: -9441.48
-10207.43
-1007.24
3-Year Revenue Growth Rate 92.80
NAS:CYCC's 3-Year Revenue Growth Rate is ranked higher than
94% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. NAS:CYCC: 92.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:CYCC' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -23 Max: 92.8
Current: 92.8
0
92.8
3-Year EBITDA Growth Rate -35.40
NAS:CYCC's 3-Year EBITDA Growth Rate is ranked lower than
84% of the 506 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. NAS:CYCC: -35.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:CYCC' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -50.2  Med: -31.7 Max: 13.8
Current: -35.4
-50.2
13.8
3-Year EPS without NRI Growth Rate -36.40
NAS:CYCC's 3-Year EPS without NRI Growth Rate is ranked lower than
81% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. NAS:CYCC: -36.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:CYCC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -52.2  Med: -32.3 Max: 22.9
Current: -36.4
-52.2
22.9
GuruFocus has detected 1 Warning Sign with Cyclacel Pharmaceuticals Inc $NAS:CYCC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:CYCC's 10-Y Financials

Financials (Next Earnings Date: 2017-03-24)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

CYCC Guru Trades in Q1 2016

Jim Simons 279,094 sh (+92.09%)
» More
Q2 2016

CYCC Guru Trades in Q2 2016

Jim Simons 44,613 sh (+91.82%)
» More
Q3 2016

CYCC Guru Trades in Q3 2016

Jim Simons 163,913 sh (+267.41%)
» More
Q4 2016

CYCC Guru Trades in Q4 2016

Jim Simons 180,213 sh (+9.94%)
» More
» Details

Insider Trades

Latest Guru Trades with CYCC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Cyclacel Pharmaceuticals Inc

SymbolPriceYieldDescription
CYCCP6.374.716% Convertible Exchangeable Preferred Stock

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:MBVX, OTCPK:OPNT, NAS:KTOV, NAS:OGXI, NAS:APTO, OTCPK:MATN, NAS:OCRX, OTCPK:BCTXF, NAS:SBOT, OTCPK:PPGNY, NAS:CBLI, OTCPK:ATTBF, NAS:GNVC, NAS:ORPN, NAS:VTGN, OTCPK:PRGB, NAS:SNGX, OTCPK:NULF, AMEX:CVM, NAS:ANTH » details
Traded in other countries:UXI3.Germany,
Cyclacel Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious diseases.

Cyclacel Pharmaceuticals Inc was founded in August 13, 1996 and is incorporated in Delaware. The Company is a biopharmaceutical company engaged in the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious diseases. The Company develops and commercializes small-molecule drugs that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, particularly those of high unmet medical need. Its clinical development priorities are focused on sapacitabine only, its second drug candidate, seliciclib, is a novel, orally-available, CDK clinical development priorities are focused on sapacitabine as an orphan drug for the treatment of both Acute Myeloid Leukemia, or AML, and Myelodysplastic Syndromes, or MDS. The Company is currently evaluating sapacitabine in a Phase 3 study being conducted under a Special Protocol Assessment, or SPA, with the FDA for the front-line treatment of AML in the elderly. The Company is also exploring sapacitabine in Phase 2 studies for MDS, non-small cell lung cancer, or NSCLC, and chronic lymphocytic leukemia, or CLL and in a Phase 1 study in solid tumors in combination with seliciclib, another of its drug candidates. Sapacitabine has been evaluated in approximately 1,000 patients to date. In addition, in polo-like kinase, or PLK inhibitor program, the Company has discovered CYC140 and other small molecule inhibitors of PLK1, a kinase active during cell division, targeting the mitotic phase of the cell cycle. The Company retains all marketing rights for these compounds internationally.

Ratios

vs
industry
vs
history
PB Ratio 0.79
CYCC's PB Ratio is ranked higher than
91% of the 975 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. CYCC: 0.79 )
Ranked among companies with meaningful PB Ratio only.
CYCC' s PB Ratio Range Over the Past 10 Years
Min: 0.22  Med: 1.91 Max: 13.13
Current: 0.79
0.22
13.13
PS Ratio 9.48
CYCC's PS Ratio is ranked higher than
55% of the 774 Companies
in the Global Biotechnology industry.

( Industry Median: 13.23 vs. CYCC: 9.48 )
Ranked among companies with meaningful PS Ratio only.
CYCC' s PS Ratio Range Over the Past 10 Years
Min: 5.02  Med: 64.6 Max: 9520
Current: 9.48
5.02
9520
EV-to-EBIT 0.30
CYCC's EV-to-EBIT is ranked higher than
98% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 17.39 vs. CYCC: 0.30 )
Ranked among companies with meaningful EV-to-EBIT only.
CYCC' s EV-to-EBIT Range Over the Past 10 Years
Min: -4.8  Med: -1 Max: 0.6
Current: 0.3
-4.8
0.6
EV-to-EBITDA 0.30
CYCC's EV-to-EBITDA is ranked higher than
99% of the 274 Companies
in the Global Biotechnology industry.

( Industry Median: 15.67 vs. CYCC: 0.30 )
Ranked among companies with meaningful EV-to-EBITDA only.
CYCC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -5  Med: -1 Max: 0.6
Current: 0.3
-5
0.6
Current Ratio 4.05
CYCC's Current Ratio is ranked higher than
50% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. CYCC: 4.05 )
Ranked among companies with meaningful Current Ratio only.
CYCC' s Current Ratio Range Over the Past 10 Years
Min: 0.96  Med: 4.02 Max: 12.96
Current: 4.05
0.96
12.96
Quick Ratio 4.05
CYCC's Quick Ratio is ranked higher than
53% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. CYCC: 4.05 )
Ranked among companies with meaningful Quick Ratio only.
CYCC' s Quick Ratio Range Over the Past 10 Years
Min: 0.96  Med: 4.02 Max: 12.96
Current: 4.05
0.96
12.96
Days Sales Outstanding 742.20
CYCC's Days Sales Outstanding is ranked lower than
99% of the 524 Companies
in the Global Biotechnology industry.

( Industry Median: 59.75 vs. CYCC: 742.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYCC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 568.15  Med: 777.81 Max: 6980.27
Current: 742.2
568.15
6980.27

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -60.40
CYCC's 3-Year Average Share Buyback Ratio is ranked lower than
90% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. CYCC: -60.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CYCC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -144.5  Med: -43 Max: 0
Current: -60.4
-144.5
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.10
CYCC's Price-to-Net-Cash is ranked higher than
92% of the 652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.34 vs. CYCC: 1.10 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CYCC' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.55  Med: 2.34 Max: 9.34
Current: 1.1
0.55
9.34
Price-to-Net-Current-Asset-Value 0.80
CYCC's Price-to-Net-Current-Asset-Value is ranked higher than
95% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. CYCC: 0.80 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CYCC' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.45  Med: 2.2 Max: 6.18
Current: 0.8
0.45
6.18
Price-to-Tangible-Book 0.80
CYCC's Price-to-Tangible-Book is ranked higher than
93% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. CYCC: 0.80 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CYCC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.41  Med: 2.13 Max: 5.9
Current: 0.8
0.41
5.9
Price-to-Median-PS-Value 0.15
CYCC's Price-to-Median-PS-Value is ranked higher than
94% of the 673 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. CYCC: 0.15 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CYCC' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.12  Med: 1.05 Max: 123.84
Current: 0.15
0.12
123.84
Earnings Yield (Greenblatt) % 335.24
CYCC's Earnings Yield (Greenblatt) % is ranked higher than
100% of the 1109 Companies
in the Global Biotechnology industry.

( Industry Median: -10.11 vs. CYCC: 335.24 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CYCC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 156.3  Med: 416.1 Max: 26714.3
Current: 335.24
156.3
26714.3

More Statistics

Revenue (TTM) (Mil) $0.99
EPS (TTM) $ -4.15
Beta5.19
Short Percentage of Float13.58%
52-Week Range $3.05 - 9.72
Shares Outstanding (Mil)4.25

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 1 2 2 2
EPS ($) -2.69 -2.25 -1.57 -1.18
EPS without NRI ($) -2.69 -2.25 -1.57 -1.18
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CYCC

Headlines

Articles On GuruFocus.com
Wilbur Ross Buys Two New Stakes in First Quarter Jun 15 2015 
Insider Cluster Buying Reported in Several Companies May 30 2013 
Cyclacel Pharmaceuticals Inc. Reports Operating Results (10-K/A) May 17 2010 
Hardest Hit Companies of the Day: Transition Therapeutics Inc., Sunesis Pharmaceuticals Inc., GenCor Dec 15 2009 

More From Other Websites
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2016 Financial Results Mar 21 2017
CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events Mar 13 2017
Cyclacel’s CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a Novel Cancer-Specific Mechanism of... Mar 07 2017
Here’s What Happened With Cyclacel Pharmaceuticals Inc (CYCC) And Nivalis Therapeutics Inc (NVLS) Feb 24 2017
Cyclacel Tanks on Leukemia Drug Failure Feb 24 2017
Biotech Movers: Shire Rises on Encouraging Angioedema Results Feb 23 2017
CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 23 2017
Cyclacel's stock plunges after disappointing trial results of its cancer treatment Feb 23 2017
Cyclacel's leukemia drug for elderly patients fails in key study Feb 23 2017
Cyclacel Announces Top-Line Results From Pivotal Phase 3 SEAMLESS Study in Elderly Patients With... Feb 23 2017
Cyclacel Pharmaceuticals to Present at the 19th Annual BIO CEO & Investor Conference Feb 06 2017
ETFs with exposure to Cyclacel Pharmaceuticals, Inc. : January 19, 2017 Jan 19 2017
ETFs with exposure to Cyclacel Pharmaceuticals, Inc. : December 29, 2016 Dec 29 2016
CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Dec 22 2016
ETFs with exposure to Cyclacel Pharmaceuticals, Inc. : December 13, 2016 Dec 13 2016
CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events Dec 09 2016
Cyclacel's Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential in Esophageal Cancer and... Dec 01 2016
CYCLACEL PHARMACEUTICALS, INC. Financials Nov 23 2016
ETFs with exposure to Cyclacel Pharmaceuticals, Inc. : November 23, 2016 Nov 23 2016
Cyclacel Pharmaceuticals, Inc. :CYCC-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21,... Nov 21 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)